NTRB
Nutriband Inc. [NTRB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NTRB Stock Summary
Top NTRB Correlated Resources
NTRB
Top 10 Correlated ETFs
NTRB
Top 10 Correlated Stocks
NTRB
In the News
NTRB Financial details
Company Rating
-
Market Cap
34.54M
Income
-5.27M
Revenue
2.09M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
-4.28
Forward P/E
-
PEG
1.16
P/S
10.8
P/B
3.95
P/C
-
P/FCF
-6.2
Quick Ratio
2
Current Ratio
2.79
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.67
EPS next Y
-
EPS next Q
-
EPS this Y
-46.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.47%
Revenue last 5Y
53.34%
Revenue Q/Q
-34.77%
EPS Q/Q
100%
-
-
-
-
SMA20
-8.55%
SMA50
51.03%
SMA100
10.13%
Inst Own
-
Inst Trans
-
ROA
-62%
ROE
-73%
ROC
-0.63%
Gross Margin
39%
Oper. Margin
-236%
Profit Margin
-252%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.53-5.927
52W High
+25.2%
52W Low
+526%
RSI
42.8
Rel Volume
0.3
Avg Volume
42.88K
Volume
13.02K
Perf Week
-4.28%
Perf Month
-17.31%
Perf Quarter
7.01%
Perf Half Y
4.16%
-
-
-
-
Beta
0.44
-
-
Volatility
0.18%, 0.41%
Prev Close
-4.72%
Price
6.26
Change
-5.15%
Company Profile
- Volume Average 42.88K
- Market Capitalization 34.54M
- Employee 13
- CEO Mr. Gareth Sheridan
- Headquarters Orlando,FL,US
- IPO Date 2021-10-01
-
Website
https://nutriband.com 
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
